Manufactured Object – Page 20

Citizen Health Secures $14.5M in Seed Funding to Revolutionize Rare Disease Care with AI-Powered Data Platform

10 months ago talkbio0Tagged AI-Powered Data Platform, Chan, Citizen, Health, Health care facility, Initiative, Personalized, Plant seeds, Rare Disease Care, Zuckerberg

Citizen Health, Rare Disease Care, AI-Powered Data Platform, Seed Funding, Chan Zuckerberg Initiative, Personalized Healthcare

Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence

10 months ago talkbio0Tagged Adherence, Adherence (attribute), Data Analytics, Health care facility, Health Equity, Market, outcomes, public health medicine (field), Social Determinants of Health

Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health

Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry

10 months ago talkbio0Tagged advancements, Aortic Valve Insufficiency, Biopharma, DNA Integration, Glucagon-Like Peptide 1, Health care facility, Healthcare technology, Impact food supplement, Ira (eukaryote), Pharmaceutical Industry Shifts, Telemedicine, trends qualifier, Value-Based Care

AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements

UnitedHealth’s Optum Defends $3.3 Billion Acquisition of Amedisys Amid DOJ Lawsuit

10 months ago talkbio0Tagged Acquisition, Amedisys, DOJ, Health care facility, Optum, UnitedHealth

Optum, Amedisys, UnitedHealth, DOJ, Acquisition, Healthcare, Antitrust

Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs

10 months ago talkbio0Tagged Autoimmune Diseases, Automobiles, Cancer Programs, deprioritization, Lupus Nephritis, NK cell therapy, Nkarta

Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization

Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A

10 months ago talkbio0Tagged Biopharma, Health care facility, Jr., M&A, Robert F. Kennedy Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.

Gilead and Arcellx Highlight Promising CAR T Therapy for Multiple Myeloma with Enhanced Safety Profile

10 months ago talkbio0Tagged Arcellx, Automobiles, Clinical Trials, Effectiveness, Gilead, Multiple Myeloma, safety profile, T therapy

CAR T therapy, multiple myeloma, anito-cel, Gilead, Arcellx, safety profile, efficacy, clinical trials

FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks

10 months ago talkbio0Tagged Autologous (qualifier value), Automobiles, BCMA, BCMA-directed, boxed, CAR-T therapy, Cautionary Warning, CD19-directed, Neoplasm Metastasis, T-cell immunotherapies, T-Lymphocyte, United States Food and Drug Administration

CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.

EU Regulators Schedule December 6 Decision on Novo Holdings’ Acquisition of Catalent

10 months ago talkbio0Tagged Acquisition, Catalent, deadline, December, December 6, EU, Holdings, Regulators (device)

EU regulators, Novo Holdings, Catalent, acquisition, antitrust review, December 6 deadline

Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration

11 months ago talkbio0Tagged Administration occupational activities, Agriculture, Biopharma, Health care facility, Policy, RFK Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy